Heterocyclic Compounds

A pharmaceutical composition containing at least one compound of formula (I)

• Y is O;
• Z is O or S;
• n is 1 or 2;
• m is 1 or 2;
• n+m is 2 or 3;
• R1 is H or C1-6alkyl;
• R2 is H, F, Cl, Br or C1-6alkyl;
• R3 and R4 are, independently, H, C1-4alkyl, C3-6cycloalkyl, C1-4alkyl(C3-6cycloalkyl), cyano, —CF3, —(CO)NRpRq, —(CO)ORr, —CH2NRpRq Or —CH2ORr;
• where Rp, Rq and Rr are independently selected from H, C1-4alkyl, C3-6cycloalkyl, phenyl, —C1-2alkyl(C3-6cycloalkyl), benzyl or phenethyl, or Rp and Rq taken together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional heteroatoms selected from O, S, NH or NC1-6alkyl, and where any phenyl or alkyl or cycloalkyl moiety of the foregoing is optionally and independently substituted with between 1 and 3 substituents selected from C1-3alkyl, halo, hydroxy, amino, and C1-3alkoxy;
• R5 and R6 are, independently, H or C1-6alkyl;
• R7 is —Ra, —RbRa, —Re—O—Ra or —Re—N(Rc)(Rd), where Ra is H, cyano, —(C═O)N(Rc)(Rd), —C(═NH)(NH2), C1-10alkyl, C2-8alkenyl, C3-8cycloalkyl, C4-7heterocyclic radical or phenyl, where the C4-7heterocyclic radical is attached at a carbon atom and contains one of O, S, NH or NC1-4alkyl, and optionally an additional NH or NC1-6alkyl in rings of 5 or 6 or 7 members, where Rb is C1-8alkylene or C2-8alkenylene, where Re is C2-8alkylene or C2-8alkenylene, where Rc and Rd are each independently H, C1-4alkyl, C2-4alkenyl, C3-6cycloalkyl or phenyl, or Rc and Rd taken together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional heteroatoms selected from O, S, NH or NC1-6alkyl, and where any phenyl or alkyl or cycloalkyl moiety of the foregoing is optionally and independently substituted with between 1 and 3 substituents selected from C1-3alkyl, halo, hydroxy, amino, and C1-3alkoxy;
• alternatively, R7 may be taken together with an adjacent R4 as well as their carbon and nitrogen of attachment to form a 5, 6 or 7 membered heterocyclic ring, with 0 or 1 additional heteroatoms selected from O, S, NH or NC1-6alkyl, and optionally and independently substituted with between 1 and 3 substituents selected from C1-3alkyl, halo, hydroxy, amino, and C1-3alkoxy;
• R8 and R9 are, independently, H, F, Cl, Br, I, C1-4alkyl, C1-4alkoxy, —C3-6cycloalkyl, —OC3-6cycloalkyl, —OCH2Ph, —CF3, —OCF3, —SCF3, —(C═O)Rk (wherein Rk is H, C1-4alkyl, —OH, phenyl, benzyl, phenethyl or C1-6alkoxy), —(N—Rt)(C═O)Rk (where Rt is H or C1-4alkyl), —(N—Rt)SO2C1-4alkyl, —(S═(O)p)—C1-4alkyl (wherein p is 0, 1 or 2), nitro, —SO2NRlRm (wherein Rl and Rm are independently selected from H, C1-4alkyl, phenyl, benzyl or phenethyl, or Rl and Rm taken together with the nitrogen to which they are attached, form a 4-7 membered heterocyclic ring with 0 or 1 additional heteroatoms selected from O, S, NH or NC1-4alkyl), —(C═O)NRlRm, cyano or phenyl, where any phenyl or alkyl or cycloalkyl moiety of the foregoing is optionally and independently substituted with between 1 and 3 substituents selected from C1-3alkyl, halo, hydroxy, amino, and C1-3alkoxy;
• and enantiomers, diastereomers and pharmaceutically acceptable salts and esters thereof,
• with the following provisos,
• that R6 adjacent to N must be H where R4 adjacent to N is other than H,
• that R7 is not —CH2CH2OH;
• and
• that where the core molecule is a 4H-furo, then one of R4 and R6 adjacent to N must not be methyl when the other is hydrogen unless R6 and R4 are taken together to form a bridging moiety.

A compound selected from the group consisting of

• (4H-Furo[3,2-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone;
• (2-Methyl-4H-furo[3,2-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone;
• (2,3-Dimethyl-4H-furo[3,2-b]pyrrol-5-yl)-(4-methyl-piperazin-1-yl)-methanone;
• (2-Methyl-4H-furo[3,2-b]pyrrol-5-yl)-piperazin-1-yl-methanone;
• and
• enantiomers, diastereomers and pharmaceutically acceptable salts and esters thereof.